News Regen BioPharma, Inc.

Equities

RGBP

US75886M3007

Market Closed - OTC Markets Other stock markets 16:50:42 27/06/2024 BST			5-day change	1st Jan Change
0.67 ^USD	-1.47%		-24.42%	-29.47%

04-24	Regen BioPharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2024	CI
02-09	Regen Biopharma, Inc. Files Provisional Patent Application for Accelerating Hematopoietic Reconstitution After an Insult or Chronic Pathology by Administration of Stem Cell Derived Endothelial Progenitor Cells or Endothelial Cells	CI

Summary

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Regen BioPharma : Material Event - Form 8-K	04-29	PU
Regen BioPharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2024	04-24	CI
Regen Biopharma, Inc. Files Provisional Patent Application for Accelerating Hematopoietic Reconstitution After an Insult or Chronic Pathology by Administration of Stem Cell Derived Endothelial Progenitor Cells or Endothelial Cells	02-09	CI
Regen BioPharma, Inc. to Present at the Emerging Growth Conference on February 7, 2024	02-05	PR
Regen BioPharma, Inc. Reports Earnings Results for the First Quarter Ended December 31, 2023	01-19	CI
Regen BioPharma, Inc. Reports Earnings Results for the Full Year Ended September 30, 2023	11-20	CI
Regen BioPharma, Inc. Outlines Future Steps in CAR T Program	11-14	CI
Regen BioPharma, Inc Receives Second Phase Confirmatory Data on its Duracar CAR-T Cell Therapy Program	25/10/23	CI
Regen Biopharma, Inc. Expects Second Phase of Confirmatory Study Shortly	18/10/23	CI
Regen BioPharma, Inc. issues Message to the Shareholders from the Chairman And Chief Executive Officer	20/09/23	AQ
Studies on Regen Biopharma, Inc.'s Duracar Indicate Potential Suppression of Autoimmunity, Company Retains Contract Research Organization to Conduct Additional Confirmatory Studies	19/09/23	CI
Regen BioPharma, Inc. announced that it has received $0.14875 million in funding	11/09/23	CI
Regen BioPharma, Inc. to Present at the Emerging Growth Conference on August 10, 2023	08/08/23	PR
Regen BioPharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2023	25/07/23	CI
Regen BioPharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2023	18/04/23	CI
REGEN BIOPHARMA INC : Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year (form 8-K)	07/02/23	AQ
Regen BioPharma Leverages Exosome Technologies to Broaden its Survivin Cancer Immunotherapy Portfolio	23/01/23	AQ
REGEN BIOPHARMA INC MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS. (form 10-Q)	19/01/23	AQ
Regen BioPharma, Inc. Reports Earnings Results for the First Quarter Ended December 31, 2022	19/01/23	CI
Regen BioPharma, Inc. Announces Board Appointments	07/12/22	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Regen BioPharma, Inc.

Equities

RGBP

US75886M3007

Summary

Filters